phenobarbital and Cytomegalic Inclusion Disease

phenobarbital has been researched along with Cytomegalic Inclusion Disease in 1 studies

Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.

Research

Studies (1)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Length of Hospitalization

This endpoint will compare length of stay in the hospital (in days) using sublingual buprenorphine or morphine solution. (NCT01452789)
Timeframe: Duration of hospital stay is an expected average of 5 weeks.

Length of Treatment

This endpoint will compare length of treatment (in days) using sublingual buprenorphine or oral morphine solution. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.

Number of Participants With Adverse Events as a Measure of Safety and Tolerability

Adverse events will be collected, graded by severity, and assessed for causality referent to study drug. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.

Number of Patients Requiring Supplemental Phenobarbital Treatment.

This endpoint will compare requirement number of patients who require use of supplemental phenobarbital. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.

Trials

1 trial available for phenobarbital and Cytomegalic Inclusion Disease